| Literature DB >> 29872395 |
Mengqian Li1, Liting You1, Jianxin Xue1, You Lu1.
Abstract
Cellular senescence is identified by a living cell in irreversible and persistent cell cycle arrest in response to various cellular stresses. Senescent cells secrete senescence-associated secretory phenotype factors that can amplify cellular senescence and alter the microenvironments. Radiotherapy, via ionizing radiation, serves as an effective treatment for local tumor control with side effects on normal cells, which can induce inflammation and fibrosis in irradiated and nearby regions. Research has revealed that senescent phenotype is observable in irradiated organs. This process starts with DNA damage mediated by radiation, after which a G2 arrest occurs in virtually all eukaryotic cells and a mitotic bypass is possibly necessary to ultimately establish cellular senescence. Within this complex DNA damage response signaling network, ataxia telangiectasia-mutated protein, p53, and p21 stand out as the crucial mediators. Senolytic agents, a class of small molecules that can selectively kill senescent cells, hold great potential to substantially reduce the side effects caused by radiotherapy while reasonably steer clear of carcinogenesis.Entities:
Keywords: DNA damage; cell cycle; cellular senescence; ionizing radiation; senolytic
Year: 2018 PMID: 29872395 PMCID: PMC5972185 DOI: 10.3389/fphar.2018.00522
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
A summary of the first publication of important small molecule senolytic agents (small molecules that can selectively kill senescent cells).
| Name of the senolytic agents | Targeted molecular | Major studied types of cell/organ/animal | Reference |
|---|---|---|---|
| AP20187 | p16INK4A expressing adipocytes | Transgenic INK-ATTAC progeroid mice ( | |
| Rapamycin or sirolimus | mTOR complex mTORC1 | (I) Partly suppressed the SASP, especially IL-1α in IR-induced SNCs ( | |
| siRNA | EFNB1 or 3, PI3KCD, p21, BCL-xL, PAI-2 | Senescent human abdominal subcutaneous preadipocytes ( | |
| Dasatinib (D)/BMS-354825 and quercetin (Q) | D: multiple tyrosine kinases Q: PI3K | (I) Selectively killing of both senescent preadipocytes, endothelial cells MEFs and MSCs ( | |
| (I) Smomelotinib (CYT387) and INCB18424 (II) Ruxolitinib (INCB18424) | JAK pathway | (I) Senescent human primary. preadipocytes ( | |
| ABT-737 | BCL-2, BCL-W, and BCL-XL | (I) Irradiated male mice ( | |
| ABT263 (a paralog of ABT-737) | BCL-2 and BCL-xL | Sublethally irradiated mice or normally aged mice ( | |
| KU-60019 | ATM kinase | (I) Human diploid fibroblasts, ATM-deficient GM02052 fibroblasts ( | |
| 17-DMAG | HSP90 | (I) Senescent Ercc1-/- primary MEFs II. Ercc1-/Δ mouse (model of a human progeroid syndrome) | |
| Fisetin, A1331852, A1155463 | Fisetin: PI3K/Akt pathway; A1331852 and A1155463: targeting BCL-XL | Specifically inducing apoptosis in SNCs. Fisetin: senescent HUVECs. A1331852 and A1155463: senescent HUVECs and IMR-90 cells | |
| FOXO4-DRI | A modified FOXO4-p53 interfering peptide | Selectively induced apoptosis of senescent cells |